C4 Therapeutics Inc (NASDAQ:CCCC)’s traded shares stood at 1.02 million during the latest session, with the company’s beta value hitting 3.05. At the last check today, the stock’s price was $6.80, to imply an increase of 6.08% or $0.39 in intraday trading. The CCCC share’s 52-week high remains $11.88, putting it -74.71% down since that peak but still an impressive 84.41% since price per share fell to its 52-week low of $1.06. The company has a valuation of $471.48M, with an average of 1.23 million shares in intraday trading volume over the past 10 days and average of 1.59 million shares over the past 3 months.

Analysts have given a consensus recommendation of Hold for C4 Therapeutics Inc (CCCC), translating to a mean rating of 1.75. Of 3 analyst(s) looking at the stock, 0 analyst(s) give CCCC a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.38.

C4 Therapeutics Inc (NASDAQ:CCCC) trade information

After registering a 6.08% upside in the latest session, C4 Therapeutics Inc (CCCC) has traded red over the past five days. The 5-day price performance for the stock is 25.92%, and 19.92% over 30 days. With these gigs, the year-to-date price performance is 20.35%. Short interest in C4 Therapeutics Inc (NASDAQ:CCCC) saw shorts transact 11.63 million shares and set a 12.18 days time to cover.

The extremes give us $9 and $15 for target low and target high price respectively. As such, CCCC has been trading -120.59% off suggested target high and -32.35% from its likely low.

C4 Therapeutics Inc (CCCC) estimates and forecasts

Looking at statistics comparing C4 Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. C4 Therapeutics Inc (CCCC) shares are -28.50% down over the last 6 months, with its year-to-date growth rate higher than industry average at 41.20% against 17.20%. The rating firms project that company’s revenue will grow 37.00% compared to the previous financial year.

Revenue forecast for the current quarter as set by 5 analysts is 4.6M. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 4.12M.Earnings reports from the last fiscal year show that sales brought in 5.46M and 3.26M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -15.80% before jumping 26.30% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -36.05% for the past 5-year period. While 2024 is set for a 46.60% return in earnings, projections for the next 5 years are at 22.30% annually.

CCCC Dividends

C4 Therapeutics Inc has its next earnings report out on 2024-Oct-30. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders

C4 Therapeutics Inc insiders hold 11.65% of total outstanding shares, with institutional holders owning 88.48% of the shares at 100.14% float percentage. In total, 88.48% institutions holds shares in the company, led by LYNX1 CAPITAL MANAGEMENT LP. As of 2024-06-30, the company held over 6.88 million shares (or 9.9993% of shares), all amounting to roughly $31.79 million.

The next major institution holding the largest number of shares is RA CAPITAL MANAGEMENT, L.P. with 4.88 million shares, or about 7.0891% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $22.54 million.